Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine is a conjugate vaccine used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Several serogroups of N. meningitidis - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.
- Mechanism
- Curator reviewed · 3 references
Neisseria meningitidis is a human-encapsulated Gram-negative diplococcus that is known to cause serious and life-threatening invasive disease. N. meningitidis has several different serogroups that are classified based on the composition of capsular polysaccharide (CPS) polymers. Among the serogroups, serogroups A, B, C, W, Y, and X account for the majority of meningococcal diseases.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine contains bacterial CPS (serogroup A, C, Y, and W-135 oligosaccharides) conjugated to a carrier protein (CRM197), allowing more robust antibody responses compared to plain polysaccharide vaccines. Upon administration, this conjugate vaccine promotes the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y, and W-135 in vaccinated individuals.
- Primary indication
- This is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age.Curator reviewed · 4 structured indications
- First approval
- Canada, 2015
- Brand names
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account